Muscarinic agents
| | | |
Pilocarpine | 5 mg/6 h po | 127 (primary + associated SS) | 81 |
| 5 mg/12 h po | 27 (primary SS) | 82 |
Cevimeline | 30 mg/8 h po | 25 (primary + associated SS) | 83 |
| | 62 (primary + associated SS) | 84 |
| | | |
Biological agents
| | | |
Infliximab | 3 mg/kg ev | 4 (SS associated with RA) | 88 |
| | 1 (primary SS + neuropathy) | 89 |
| | 16 (primary SS) | 86, 87 |
| 5 mg/kg ev | 54 (primary SS) | 90 |
Etanercept | 25 mg/12 h sc | 15 (primary SS) | 91 |
Rituximab | 375 mg/m2 ev | 1 (primary SS + lymphoma) | 98 |
| | 1 (primary SS + lymphoma) | 99 |
IFNα | 150 IU/8 h po | 300 (primary SS) | 94 |
| | | |
Other treatments
| | | |
Prednisolone | 15 mg/d po | 20 (primary SS) | 101 |
Octreotide | 30 mg im | 1 (primary SS) | 107 |
2-Chloro-2′-deoxyadenosine | 0.12 mg/kg ev | 2 (primary SS + lymphoma) | 106 |
| | 2 (primary SS + MC) | |